Akebia Therapeutics (AKBA) Price & Analysis

Compare

1,495 Followers

AKBA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.24 - $4.08

Previous CloseN/A

Volume5.66M

Average Volume (3M)3.85M

Market Cap

$819.30M

Enterprise Value$1.06B

Total Cash (Recent Filing)$137.31M

Total Debt (Recent Filing)$53.36M

Price to Earnings (P/E)―

Beta1.32

Next Earnings

Nov 06, 2025

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding265,145,050

10 Day Avg. Volume3,869,773

30 Day Avg. Volume3,847,357

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.29

Enterprise Value/Revenue5.20

Enterprise Value/Gross Profit6.99

Enterprise Value/Ebitda96.31

Forecast

1Y Price Target

$7.00

Price Target Upside132.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

PartnershipsAkebia's partnership with DaVita represents a significant competitive advantage given DaVita's market leadership in controlling the majority of dialysis care delivery.

Patient AccessVafseo will now be accessible to over 55,000 patients through dialysis provider protocols, indicating a more optimistic long-term view.

Revenue GrowthThe revenue estimate for Auryxia was raised by approximately 80% due to its stability in the first half of the year.

Bears Say

Generic CompetitionAURYXIA lost intellectual property exclusivity in March 2025, with an authorized generic expected to reduce the contribution to total revenues over time as additional potential generic competition is introduced.

Market SaturationVafseo revenues fell below expectations as growth moderated, likely reflecting saturation of the current patient addressable base.

Revenue PerformanceThe FY25E revenue estimate for Vafseo was reduced by approximately 13% due to weaker than expected performance.

Akebia Therapeutics News

Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Akebia (AKBA) Therapeutics and Innovative Renal Care announced the broad availability of Vafseo for the treatment of anemia...

8d ago

AKBA

Akebia reports Q2 EPS 0c vs (4c) last year

Reports Q2 revenue $62.472M, consensus $47.24M. “Vafseo U.S. product launch momentum builds as we continued to add new...

22d ago

AKBA

Akebia initiates post-marketing study to identify benefits of Vafseo

Akebia (AKBA) Therapeutics announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo. The...

25d ago

AKBA

Akebia Therapeutics Reports Record Revenue and Strategic Growth

Akebia Therapeutics (($AKBA)) has held its Q2 earnings call. Read on for the main highlights of the call....

16d ago

AKBA

Akebia Therapeutics Reports Strong Q2 2025 Growth

Akebia Therapeutics ( ($AKBA) ) has released its Q2 earnings. Here is a breakdown of the information Akebia...

21d ago

AKBA

Strategic Partnerships and Clinical Trials Propel Akebia Therapeutics’ Growth Potential

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AKBA stock, giving a Buy rating on...

23d ago

AKBA

Akebia Therapeutics (AKBA) Q2 Earnings Cheat Sheet

Akebia Therapeutics (AKBA) is scheduled to report 2nd quarter earnings on 08/07/2025, before the market opens. Regarding Q2...

24d ago

AKBA

Akebia Therapeutics Approves Stock Plan Amendment at Meeting

Akebia Therapeutics ( ($AKBA) ) has shared an announcement. At its Annual Meeting on June 10, 2025, Akebia...

3M ago

AKBA

International Paper, ImmunityBio, Agenus, Akebia, Apple: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($IP) ), ( ($IBRX) ), ( ($AGEN) ), ( ($AKBA)...

3M ago

AAPL

Akebia announces JASN published analysis from vadadustat phase 3 program

Akebia (AKBA) Therapeutics announced that the Journal of the American Society of Nephrology, JASN, has published pre-specified analyses...

3M ago

AKBA

Buy Rating for Akebia Therapeutics Driven by VAFSEO’s Market Potential in CKD Anemia

Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rating on Akebia Therapeutics (AKBA). Matthew...

3M ago

AKBA

Akebia assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield assumed coverage of Akebia (AKBA) with a Buy rating and $8 price target...

3M ago

AKBA

Akebia Therapeutics’ Growth Potential Driven by Vafseo’s Market Expansion and Upcoming VALOR Trial

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) yesterday and...

3M ago

AKBA

Akebia Therapeutics: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

In a report released on May 9, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Akebia...

4M ago

AKBA

AKBA FAQ

What was Akebia Therapeutics’s price range in the past 12 months?

Akebia Therapeutics lowest stock price was $1.24 and its highest was $4.08 in the past 12 months.

What is Akebia Therapeutics’s market cap?

Akebia Therapeutics’s market cap is $819.30M.

When is Akebia Therapeutics’s upcoming earnings report date?

Akebia Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Akebia Therapeutics’s earnings last quarter?

Akebia Therapeutics released its earnings results on Aug 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.015.

Is Akebia Therapeutics overvalued?

According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akebia Therapeutics pay dividends?

Akebia Therapeutics does not currently pay dividends.

What is Akebia Therapeutics’s EPS estimate?

Akebia Therapeutics’s EPS estimate is -0.03.

How many shares outstanding does Akebia Therapeutics have?

Akebia Therapeutics has 265,145,050 shares outstanding.

What happened to Akebia Therapeutics’s price movement after its last earnings report?

Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went down -20.37%.

Which hedge fund is a major shareholder of Akebia Therapeutics?

Currently, no hedge funds are holding shares in AKBA

Akebia Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

91.25%

Trailing 12-Months

Asset Growth

56.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics (AKBA) Earnings & Revenues

Historic Earnings Reports

AKBA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call was largely positive, with strong revenue growth driven by both Vafseo and Auryxia, significant advancements in clinical trials, and an overall solid financial position. While there were some challenges with adherence rates and potential future competition for Auryxia, the positive aspects and future prospects significantly outweighed the negative points.View all AKBA earnings summaries

AKBA Stock 12 Month Forecast

Average Price Target

$7.00

▲(132.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,4.049230769230769,4.378461538461538,4.707692307692308,5.036923076923077,5.366153846153846,5.695384615384615,6.024615384615384,6.3538461538461535,6.683076923076923,7.012307692307692,7.341538461538461,7.6707692307692295,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,3.9723076923076923,4.224615384615385,4.476923076923077,4.729230769230769,4.981538461538461,5.233846153846153,5.486153846153846,5.7384615384615385,5.990769230769231,6.243076923076924,6.495384615384616,6.747692307692308,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,3.8953846153846157,4.070769230769231,4.246153846153846,4.421538461538462,4.596923076923077,4.772307692307693,4.947692307692307,5.123076923076923,5.298461538461538,5.473846153846154,5.649230769230769,5.8246153846153845,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >